UY27543A1 - Derivados de piridona de benzotiazol - Google Patents
Derivados de piridona de benzotiazolInfo
- Publication number
- UY27543A1 UY27543A1 UY27543A UY27543A UY27543A1 UY 27543 A1 UY27543 A1 UY 27543A1 UY 27543 A UY27543 A UY 27543A UY 27543 A UY27543 A UY 27543A UY 27543 A1 UY27543 A1 UY 27543A1
- Authority
- UY
- Uruguay
- Prior art keywords
- lower alkyl
- disease
- piridona
- benzotiazol
- derivatives
- Prior art date
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 3
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 239000001961 anticonvulsive agent Substances 0.000 abstract 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 2
- 208000011117 substance-related disease Diseases 0.000 abstract 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 abstract 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 229960005305 adenosine Drugs 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 229940025084 amphetamine Drugs 0.000 abstract 1
- 230000003556 anti-epileptic effect Effects 0.000 abstract 1
- 229940125681 anticonvulsant agent Drugs 0.000 abstract 1
- 229960003965 antiepileptics Drugs 0.000 abstract 1
- 239000000164 antipsychotic agent Substances 0.000 abstract 1
- 229940005529 antipsychotics Drugs 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 229930003827 cannabinoid Natural products 0.000 abstract 1
- 239000003557 cannabinoid Substances 0.000 abstract 1
- 229940065144 cannabinoids Drugs 0.000 abstract 1
- 229940045200 cardioprotective agent Drugs 0.000 abstract 1
- 239000012659 cardioprotective agent Substances 0.000 abstract 1
- 229960003920 cocaine Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 229960004756 ethanol Drugs 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 229940035363 muscle relaxants Drugs 0.000 abstract 1
- 239000003158 myorelaxant agent Substances 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
- 229960002715 nicotine Drugs 0.000 abstract 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
- 229940005483 opioid analgesics Drugs 0.000 abstract 1
- -1 opioids Chemical compound 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 229940125723 sedative agent Drugs 0.000 abstract 1
- 239000000932 sedative agent Substances 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos de fórmula general R es fenilo, piridin- 2- ilo, - C ( O)-morfolinilo, .C(O)-NR! 2, -(CH2) n- NR! 2 ó - (CH2) n - O -alquilo inferior, y R, puede ser hidrógeno o alquilo inferior; y a las sales de adición farmacéuticamente aceptable. Pueden emplearse en el control o prevención de enfermedades basadas en la modulación del sistema de la adenosina, tales como la enfermedad de Alzheimer, de Parkinson, de Huntington, neuroproteción, esquizofrenia, ansiedad, dolor, déficit respiratorios, depresión, adición a la drogas, como la anfetamina, cocaína, opioides, etanol, nicotina, cannabinoides, contra el asma, repuestas alérgicas, hipoxia, isquimia, ataques, abuso de substancias. Pueden ser de utilidad como sedantes, relajantes musculares, antipsicóticos, antiepilépticos, anticonvulsivos y agentes cardioprotectores para transtornos como la enfermedad de la arteria coronaria y fallo cardíaco. cariaco.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01127313 | 2001-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY27543A1 true UY27543A1 (es) | 2003-05-30 |
Family
ID=8179264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY27543A UY27543A1 (es) | 2001-11-19 | 2002-11-18 | Derivados de piridona de benzotiazol |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6599901B1 (es) |
| EP (1) | EP1448196B1 (es) |
| JP (1) | JP4216192B2 (es) |
| KR (1) | KR100577109B1 (es) |
| CN (1) | CN100346792C (es) |
| AR (1) | AR037528A1 (es) |
| AT (1) | ATE306265T1 (es) |
| AU (1) | AU2002366194B8 (es) |
| BR (1) | BR0214221A (es) |
| CA (1) | CA2467551A1 (es) |
| DE (1) | DE60206652T2 (es) |
| ES (1) | ES2249639T3 (es) |
| GT (1) | GT200200233A (es) |
| MX (1) | MXPA04004683A (es) |
| PA (1) | PA8557901A1 (es) |
| PE (1) | PE20030715A1 (es) |
| PL (1) | PL369470A1 (es) |
| RU (1) | RU2295523C2 (es) |
| TW (1) | TW200407137A (es) |
| UY (1) | UY27543A1 (es) |
| WO (1) | WO2003043634A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE521512C2 (sv) | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
| US6727247B2 (en) * | 2001-12-10 | 2004-04-27 | Hoffman-La Roche Inc. | Substituted benzothiazole amide derivatives |
| DE60313216T2 (de) | 2002-12-20 | 2008-01-03 | Niconovum Ab | Chemisch und physikalisch stabiles teilchenförmiges material enthaltend nikotin und microcrystalline cellulose |
| BRPI0414266A (pt) * | 2003-09-19 | 2006-11-07 | Hoffmann La Roche | derivados de tiazolopiridina como ligandos receptores da adenosina |
| JP4842829B2 (ja) | 2003-10-31 | 2011-12-21 | 武田薬品工業株式会社 | 含窒素縮合複素環化合物 |
| JP2008506735A (ja) * | 2004-07-22 | 2008-03-06 | エフ．ホフマン−ラ ロシュ アーゲー | 置換されているベンゾチアゾール類 |
| JP5202946B2 (ja) * | 2004-07-22 | 2013-06-05 | エフ．ホフマン−ラ ロシュ アーゲー | ベンゾチアゾール誘導体 |
| ES2273599B1 (es) * | 2005-10-14 | 2008-06-01 | Universidad De Barcelona | Compuestos para el tratamiento de la fibrilacion auricular. |
| EP1998748B1 (en) | 2006-03-16 | 2015-01-14 | NicoNovum AB | Improved snuff composition |
| EP2073797A2 (en) * | 2006-10-11 | 2009-07-01 | Alpharma, Inc. | Pharmaceutical compositions |
| UA96015C2 (en) * | 2007-04-04 | 2011-09-26 | Mepk Шарп Энд Доме Корп. | Therapeutic agents |
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| KR20180095674A (ko) | 2015-12-22 | 2018-08-27 | 조게닉스 인터내셔널 리미티드 | 대사 저항성 펜플루라민 유사체 및 그 사용 방법 |
| SG11201804811WA (en) | 2015-12-22 | 2018-07-30 | Zogenix International Ltd | Fenfluramine compositions and methods of preparing the same |
| RU2746000C2 (ru) | 2016-08-24 | 2021-04-05 | Зодженикс Интернэшнл Лимитед | Состав для ингибирования образования агонистов 5-ht2b и способы его применения |
| US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| JP2021526507A (ja) | 2018-05-11 | 2021-10-07 | ゾゲニクス インターナショナル リミテッド | 発作により誘発される突然死を処置するための組成物および方法 |
| US10517841B1 (en) * | 2018-06-14 | 2019-12-31 | Zogenix International Limited | Compositions and methods for treating respiratory depression with fenfluramine |
| US12144787B2 (en) | 2018-11-19 | 2024-11-19 | Zogenix International Limited | Method of treating patients with a mutation in cyclin-dependent kinase-like 5 (CDKL5) |
| DE102019110904B4 (de) | 2019-04-26 | 2022-01-20 | Helmholtz-Zentrum Dresden - Rossendorf E. V. | N-(4-methoxy-7-morpholinobenzo[d]thiazol-2-yl)-acetamid-Derivate und deren Verwendung |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0113219B1 (en) | 1982-12-21 | 1987-11-19 | Johnsen & Jorgensen (Plastics) Limited | Dispensing container |
| IL90337A0 (en) * | 1988-05-24 | 1989-12-15 | Pfizer | Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents |
| JP3886897B2 (ja) * | 2000-06-21 | 2007-02-28 | エフ．ホフマン−ラ ロシュ アーゲー | ベンゾチアゾール誘導体 |
-
2002
- 2002-11-05 US US10/288,531 patent/US6599901B1/en not_active Expired - Fee Related
- 2002-11-09 PL PL02369470A patent/PL369470A1/xx not_active Application Discontinuation
- 2002-11-09 DE DE60206652T patent/DE60206652T2/de not_active Expired - Fee Related
- 2002-11-09 EP EP02803360A patent/EP1448196B1/en not_active Expired - Lifetime
- 2002-11-09 JP JP2003545315A patent/JP4216192B2/ja not_active Expired - Fee Related
- 2002-11-09 CA CA002467551A patent/CA2467551A1/en not_active Abandoned
- 2002-11-09 MX MXPA04004683A patent/MXPA04004683A/es active IP Right Grant
- 2002-11-09 WO PCT/EP2002/012543 patent/WO2003043634A1/en not_active Ceased
- 2002-11-09 BR BR0214221-0A patent/BR0214221A/pt not_active IP Right Cessation
- 2002-11-09 AT AT02803360T patent/ATE306265T1/de not_active IP Right Cessation
- 2002-11-09 KR KR1020047007646A patent/KR100577109B1/ko not_active Expired - Fee Related
- 2002-11-09 AU AU2002366194A patent/AU2002366194B8/en not_active Ceased
- 2002-11-09 RU RU2004118423/04A patent/RU2295523C2/ru not_active IP Right Cessation
- 2002-11-09 CN CNB028228901A patent/CN100346792C/zh not_active Expired - Fee Related
- 2002-11-09 ES ES02803360T patent/ES2249639T3/es not_active Expired - Lifetime
- 2002-11-14 TW TW091133382A patent/TW200407137A/zh unknown
- 2002-11-14 PA PA20028557901A patent/PA8557901A1/es unknown
- 2002-11-15 AR ARP020104398A patent/AR037528A1/es not_active Application Discontinuation
- 2002-11-15 PE PE2002001103A patent/PE20030715A1/es not_active Application Discontinuation
- 2002-11-18 UY UY27543A patent/UY27543A1/es not_active Application Discontinuation
- 2002-11-18 GT GT200200233A patent/GT200200233A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GT200200233A (es) | 2003-06-17 |
| ES2249639T3 (es) | 2006-04-01 |
| US6599901B1 (en) | 2003-07-29 |
| AR037528A1 (es) | 2004-11-17 |
| PA8557901A1 (es) | 2003-06-30 |
| CN100346792C (zh) | 2007-11-07 |
| CN1589146A (zh) | 2005-03-02 |
| AU2002366194A1 (en) | 2003-06-10 |
| EP1448196B1 (en) | 2005-10-12 |
| CA2467551A1 (en) | 2003-05-30 |
| RU2004118423A (ru) | 2006-01-10 |
| JP4216192B2 (ja) | 2009-01-28 |
| TW200407137A (en) | 2004-05-16 |
| EP1448196A1 (en) | 2004-08-25 |
| ATE306265T1 (de) | 2005-10-15 |
| JP2005515980A (ja) | 2005-06-02 |
| DE60206652D1 (de) | 2006-02-23 |
| WO2003043634A1 (en) | 2003-05-30 |
| PL369470A1 (en) | 2005-04-18 |
| DE60206652T2 (de) | 2006-06-22 |
| PE20030715A1 (es) | 2003-08-29 |
| KR20050044537A (ko) | 2005-05-12 |
| BR0214221A (pt) | 2004-09-21 |
| MXPA04004683A (es) | 2004-08-12 |
| AU2002366194B8 (en) | 2006-11-16 |
| KR100577109B1 (ko) | 2006-05-10 |
| RU2295523C2 (ru) | 2007-03-20 |
| AU2002366194B2 (en) | 2006-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY27543A1 (es) | Derivados de piridona de benzotiazol | |
| YU96502A (sh) | Derivati benzotiazola | |
| BR0108611A (pt) | Moduladores de receptor de adenosina | |
| SE0104334D0 (sv) | Therapeutic agents | |
| GB0421639D0 (en) | Methods and compositions relating to alzheimer's disease | |
| ATE188118T1 (de) | Zusammenfassungen und ihren verwendung in der behandlung von neurologischen krankheiten | |
| DE69130570D1 (de) | Heterozyklische verbindungen, ihre herstellung und anwendung | |
| DE60135108D1 (de) | Dermale zusammenstellungen die als wirkstoff coenzym q enthalten | |
| ATE187642T1 (de) | Verwendund von norastemizol zur behandlung der allergischen rhinitis | |
| ECSP067018A (es) | (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)amida del acido 4-hidroxi-4-metil-piperidin-1-carboxilico | |
| AR037457A1 (es) | Compuestos derivados de benzotiazol, su empleo, un procedimiento para prepararlos y medicamentos que los contienen | |
| AR037221A1 (es) | Compuestos derivados de piridina, uso de los mismos, un procedimiento para su preparacion y un medicamento que contiene uno o mas de dichos compuestos | |
| SG140605A1 (en) | Benzothiazole derivatives | |
| KR910000647A (ko) | 나프틸아미노-및 나프틸옥시- 피리딘아민 및 관련된 화합물, 이의 제조방법 및 이의 피부소염제로서의 용도 | |
| AR049998A1 (es) | BENZOTIAZOLES SUSTITUIDOS COMO LIGANDOS DEL RECEPTOR DE ADENOSINA, PROCESO DE PREPARACIoN Y SU USO | |
| AR037792A1 (es) | Compuestos derivados de benzotiazol, su uso, un procedimiento para su obtencion y medicamentos que los contienen | |
| DK121789D0 (da) | 4,5,6,7-tetrahydroisothiazole oe4,5-caapyridinderivater | |
| UY27574A1 (es) | Uso de ureas de benzotiazoles | |
| ATE468334T1 (de) | Benzopyranylheterocyclylderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen | |
| EP0127529A3 (fr) | N-oxydes de dérivés aminocycliques, leur procédé de préparation et leur application en thérapeutique | |
| JO2502B1 (en) | 4-Hydroxy-4-methyl-piperidine-1-carboxylic acid-4) methoxy-7-morpholine-4-yl-benzothiazole-2-yl) -amide | |
| GT199900177A (es) | Derivados de adenina | |
| YU36499A (sh) | Primena 1-/4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropirid -1-il/2-(6,7-dimetoksinaft-2-il)etana za dobijanje medikamenata za neurotrofno dejstvo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20150126 |